Sylvester Comprehensive Cancer Center

  • 20230227 - Diamond Benjamin

  • Investigator:
    Benjamin Diamond
    RCname Email

    		Coordinator:

    IRB: 20230227

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients with Relapsed/Refractory Multiple Myeloma
    Eligibility Criteria - NCT05896228 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231300 - Hoffman James

  • Investigator:
    James Hoffman
    RCname Email

    		Coordinator:

    IRB: 20231300

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: ABBVIE

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis
    Eligibility Criteria - NCT06158854 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240173 - Hoffman James

  • Investigator:
    James Hoffman
    RCname Email

    		Coordinator:

    IRB: 20240173

    		SDG: Multiple Myeloma
    Disease Site(s):

    Bones and Joints
    Sponsor: SWOG

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Sylvester
    UMH
    Title:

    A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients With Newly Diagnosed AL Amyloidosis
    Eligibility Criteria - NCT06022939 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210835 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    		Coordinator:

    IRB: 20210835

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: BEIGENE

    Enrolling Sites:

    Gables
    Sylvester
    Title:

    A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
    Eligibility Criteria - NCT04973605 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220421 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    		Coordinator:
    RCemailImg Alanna Vossen
    RCphone +1 (305) 2437701

    IRB: 20220421

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: Janssen

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 3 Randomized Study Comparing Bortezomib, enalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
    Eligibility Criteria - NCT04923893 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220595 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    		Coordinator:

    IRB: 20220595

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)
    Eligibility Criteria - NCT05530421 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220955 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    		Coordinator:

    IRB: 20220955

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: ABBVIE

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
    Eligibility Criteria - NCT05259839 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230236 - Kazandjian Dickran

  • Investigator:
    Dickran Kazandjian
    RCname Email

    		Coordinator:

    IRB: 20230236

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    IMMUNOPLANT: Immuno-consolidation for newly diagnosed Multiple Myeloma Using lack of MRD Negativity after initial cOmbination therapy to Pursue deeper responses with Linvoseltamab ANd delay Transplant
    Eligibility Criteria - NCT06376526 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201316 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    		Coordinator:
    RCemailImg Alanna Vossen
    RCphone +1 (305) 2437701

    IRB: 20201316

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Moffitt Cancer Center
    Plantation
    Sylvester
    UMH
    Title:

    Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)
    Eligibility Criteria - NCT04268498 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201536 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    		Coordinator:

    IRB: 20201536

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: NCI

    Enrolling Sites:

    Deerfield
    Sylvester
    Title:

    A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications
    Eligibility Criteria - NCT04814615 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210341 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    		Coordinator:
    RCemailImg Alanna Vossen
    RCphone +1 (305) 2437701

    IRB: 20210341

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: PFIZER

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    MagnetisMM-4 A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA
    Eligibility Criteria - NCT05090566 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221148 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    		Coordinator:

    IRB: 20221148

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    Teclistamab or Talquetamab in Combination with Daratumumab SC for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Sequential Cohort Immuno-oncology Study to REVIVE Early Myeloma
    Eligibility Criteria - NCT06100237 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230685 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    		Coordinator:

    IRB: 20230685

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester
    Title:

    A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Eligibility Criteria - NCT05675449 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230969 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    		Coordinator:

    IRB: 20230969

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple Myeloma
    Sponsor: Janssen

    Enrolling Sites:

    Gables
    Sylvester
    UMH
    Title:

    A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
    Eligibility Criteria - NCT05572515 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231309 - Landgren Carl

  • Investigator:
    Carl Landgren
    RCname Email

    		Coordinator:

    IRB: 20231309

    		SDG: Multiple Myeloma
    Disease Site(s):

    Multiple
    Sponsor: Janssen

    Enrolling Sites:

    Gables
    Sylvester
    UMH
    Title:

    A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
    Eligibility Criteria - NCT05438043 *This information has been extracted from " www.clinicaltrials.gov"